⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17057342 | 1.00 | — | — | |
| SCHEMBL1394033 | 1.00 | — | — | |
| SCHEMBL25960786 | 1.00 | — | — | |
| SCHEMBL18636553 | 1.00 | — | — | |
| SCHEMBL12457734 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL31566713 | 0.97 | CHRNB2 (0.46) | — | |
| Hydrochloric Acid SCHEMBL7850055 | 0.97 | CHRNB2 (0.46) | — | |
| Hydrochloric Acid SCHEMBL27195898 | 0.97 | CHRNB2 (0.46) | — | |
| Hydrochloric Acid SCHEMBL7850056 | 0.97 | CHRNB2 (0.46) | — | |
| Hydrochloric Acid SCHEMBL15058446 | 0.97 | CHRNB2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110248939-A | tyrosine amide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2019-09-17 | — | — | CN | claimed |
| CN-106661019-A | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | 奇斯药制品公司 | 2017-05-10 | — | — | CN | claimed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| WO-2025242908-A2 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025133338-A1 | QUINOLONE DERIVATVES AGAINST CANCER | GENOME THERAPEUTICS LTD (GB) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025125302-A1 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-06-19 | — | — | WO | disclosed |
| CN-115916771-B | Multi-target antitumor compound and preparation method and application thereof | 浙江华海药业股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-0523512-B1 | 8-vinyl- and 8-ethinyl-quinolone carboxylic acids | BAYER AG (DE) | 1997-01-15 | — | — | EP | disclosed |
| US-5578604-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-26 | — | — | US | disclosed |
| US-5545642-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
| US-5468742-A | Antibacterial agents, feed additives | BAYER AKTIENGESELLSCHAFT (DE) | 1995-11-21 | — | — | US | disclosed |
| EP-0671391-A1 | 5-Vinyl- and 5-ethinyl-quinolinone- and -naphthyridone-carboxylic acids | BAYER AG (DE) | 1995-09-13 | — | — | EP | disclosed |
| EP-0653425-A1 | 1-(2-Fluorocyclopropyl)-quinolone- and naphthyridone carboxylic acid derivatives, their preparation and their use as antibacterials | BAYER AG (DE) | 1995-05-17 | — | — | EP | disclosed |
| EP-0523512-A1 | 8-vinyl- and 8-ethinyl-quinolone carboxylic acids | BAYER AG (DE) | 1993-01-20 | — | — | EP | disclosed |
| US-5179090-A | Antiischemic agents; treatment of asthma, bronchitis, heart diseases | DR. KARL THOMAE GMBH (DE) | 1993-01-12 | — | — | US | disclosed |
| EP-0417630-A2 | Condensed diazepinones, process for their preparation, and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1991-03-20 | — | — | EP | disclosed |